Gail Eckhardt

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook et al. · The Lancet Oncology · 2012 · 558 citations

Medicine, Pharmacokinetics, Pharmacology +11

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

Ian Ganly, David H. Kirn, Gail Eckhardt et al. · PubMed · 2000 · 439 citations

Medicine, Oncology, Pharmacotherapy +16

Activating <i>NOTCH1</i> Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors

Renata Ferrarotto, Yoshitsugu Mitani, Lixia Diao et al. · Journal of Clinical Oncology · 2017 · 245 citations · Full text

Veterinary Medicine, Molecular Biology, Oncology +17

In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

Elżbieta Izbicka, R. A. Lawrence, Éric Raymond et al. · Annals of Oncology · 1998 · 136 citations · Full text

Medicine, Oncology, Pharmacology +11

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors

Renata Ferrarotto, Gail Eckhardt, Akash Patnaik et al. · Annals of Oncology · 2018 · 136 citations · Full text

Medicine, Oncology, Pharmacology +17